Agilent

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agilent and other ETFs, options, and stocks.

About A

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. 

CEO
Padraig Mcdonnell
CEOPadraig Mcdonnell
Employees
18,100
Employees18,100
Headquarters
Santa Clara, California
HeadquartersSanta Clara, California
Founded
1999
Founded1999
Employees
18,100
Employees18,100

A Key Statistics

Market cap
32.62B
Market cap32.62B
Price-Earnings ratio
25.46
Price-Earnings ratio25.46
Dividend yield
0.87%
Dividend yield0.87%
Average volume
2.05M
Average volume2.05M
High today
$117.22
High today$117.22
Low today
$112.99
Low today$112.99
Open price
$114.18
Open price$114.18
Volume
1.05M
Volume1.05M
52 Week high
$160.27
52 Week high$160.27
52 Week low
$96.43
52 Week low$96.43

Stock Snapshot

As of today, Agilent(A) shares are valued at $115.48. The company's market cap stands at 32.62B, with a P/E ratio of 25.46 and a dividend yield of 87.1%.

During the trading session on 2026-04-05, Agilent(A) shares reached a daily high of $117.22 and a low of $112.99. At a current price of $115.48, the stock is +2.2% higher than the low and still -1.5% under the high.

Trading volume for Agilent(A) stock has reached 1.05M, versus its average volume of 2.05M.

Over the past 52 weeks, Agilent(A) stock has traded between a high of $160.27 and a low of $96.43.

Over the past 52 weeks, Agilent(A) stock has traded between a high of $160.27 and a low of $96.43.

A News

Simply Wall St 19h
Agilent Technologies Valuation Check After New Cell Imaging And Cancer Diagnostic Milestones

Agilent Technologies (A) has just added two fresh product milestones: the BioTek Cytation 9 cell imaging multimode reader and an FDA cleared PD-L1 IHC 22C3 comp...

Agilent Technologies Valuation Check After New Cell Imaging And Cancer Diagnostic Milestones
TipRanks 2d
Agilent Announces Transition Plan for Chief Legal Officer

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 2d
Is It Time To Revisit Agilent Technologies After Recent Share Price Weakness

Wondering if Agilent Technologies at around US$114.54 is offering good value right now, or if the market price is already baking in most of the upside. The sto...

Is It Time To Revisit Agilent Technologies After Recent Share Price Weakness

Analyst ratings

82%

of 22 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

More A News

TipRanks 4d
Agilent announces BioTek Cytation 9 cell imaging multimode reader

Agilent (A) Technologies announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining mu...

Simply Wall St 5d
Is New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies?

In March 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved com...

Is New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies?

People also own

Based on the portfolios of people who own A. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.